XIIDRA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Xiidra, and when can generic versions of Xiidra launch?
Xiidra is a drug marketed by Bausch And Lomb Inc and is included in one NDA. There are sixteen patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and fifty-four patent family members in twenty-five countries.
The generic ingredient in XIIDRA is lifitegrast. Three suppliers are listed for this compound. Additional details are available on the lifitegrast profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Xiidra
A generic version of XIIDRA was approved as lifitegrast by INGENUS PHARMS LLC on October 3rd, 2024.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for XIIDRA?
- What are the global sales for XIIDRA?
- What is Average Wholesale Price for XIIDRA?
Summary for XIIDRA
| International Patents: | 154 |
| US Patents: | 16 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 45 |
| Clinical Trials: | 12 |
| Patent Applications: | 259 |
| Drug Prices: | Drug price information for XIIDRA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for XIIDRA |
| What excipients (inactive ingredients) are in XIIDRA? | XIIDRA excipients list |
| DailyMed Link: | XIIDRA at DailyMed |
Recent Clinical Trials for XIIDRA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| State University of New York College of Optometry | Phase 4 |
| Novartis Pharmaceuticals | Phase 4 |
| Bucci Laser Vision Institute | Phase 4 |
Pharmacology for XIIDRA
| Drug Class | Lymphocyte Function-Associated Antigen-1 Antagonist |
| Mechanism of Action | Lymphocyte Function-Associated Antigen-1 Antagonists |
Paragraph IV (Patent) Challenges for XIIDRA
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| XIIDRA | Ophthalmic Solution | lifitegrast | 5% | 208073 | 4 | 2020-07-13 |
US Patents and Regulatory Information for XIIDRA
XIIDRA is protected by sixteen US patents.
Patents protecting XIIDRA
Modulators of cellular adhesion
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Modulators of cellular adhesion
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Modulators of cellular adhesion
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
Modulators of cellular adhesion
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
Modulators of cellular adhesion
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compositions and methods for treatment of eye disorders
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compositions and methods for treatment of eye disorders
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
Crystalline pharmaceutical and methods of preparation and use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
Compositions and methods for treatment of eye disorders
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
Crystalline pharmaceutical and methods of preparation and use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
LFA-1 inhibitor and methods of preparation and polymorph thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Modulators of cellular adhesion
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Crystalline pharmaceutical and methods of preparation and use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Crystalline pharmaceutical and methods of preparation and use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
Crystalline pharmaceutical and methods of preparation and use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |
| Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |
| Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for XIIDRA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for XIIDRA
When does loss-of-exclusivity occur for XIIDRA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 08317473
Patent: Compositions and methods for treatment of diabetic retinopathy
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 02984
Patent: COMPOSITIONS ET PROCEDES POUR LE TRAITEMENT DE LA RETINOPATHIE DIABETIQUE (COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY)
Estimated Expiration: ⤷ Sign Up
Patent: 58665
Patent: COMPOSITIONS ET PROCEDES POUR LE TRAITEMENT DE LA RETINOPATHIE DIABETIQUE (COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY)
Estimated Expiration: ⤷ Sign Up
Patent: 05972
Patent: COMPOSITIONS ET PROCEDES POUR LE TRAITEMENT DE LA RETINOPATHIE DIABETIQUE (COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY)
Estimated Expiration: ⤷ Sign Up
China
Patent: 1873797
Patent: Compositions and methods for treatment of diabetic retinopathy
Estimated Expiration: ⤷ Sign Up
Patent: 2056485
Patent: Topical LFA-1 antagonists for use in localized treatment of immune related disorders
Estimated Expiration: ⤷ Sign Up
Patent: 2065694
Patent: Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders
Estimated Expiration: ⤷ Sign Up
Patent: 2065893
Patent: Delivery of LFA-1 antagonists to the gastrointestinal system
Estimated Expiration: ⤷ Sign Up
Patent: 5943534
Patent: 用于局部治疗免疫相关疾病的局部LFA-1拮抗剂 (Topical LFA-1 antagonists for use in localized treatment of immune related disorders)
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 09371
Patent: COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE LA RÉTINOPATHIE DIABÉTIQUE (COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY)
Estimated Expiration: ⤷ Sign Up
Patent: 65124
Patent: ANTAGONISTES DE LFA-1 SOUS FORME D'AÉROSOL UTILISÉS EN TRAITEMENT LOCALISÉ DE TROUBLES DE NATURE IMMUNITAIRE (AEROSOLIZED LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS)
Estimated Expiration: ⤷ Sign Up
Patent: 65125
Patent: ANTAGONISTES DE LFA-1 TOPIQUES UTILISÉS DANS LE TRAITEMENT LOCALISÉ DE TROUBLES DE NATURE IMMUNITAIRE (TOPICAL LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS)
Estimated Expiration: ⤷ Sign Up
Patent: 76508
Patent: ADMINISTRATION D'ANTAGONISTES DE LFA-1 AU SYSTÈME GASTRO-INTESTINAL (DELIVERY OF LFA-1 ANTAGONISTS TO THE GASTROINTESTINAL SYSTEM)
Estimated Expiration: ⤷ Sign Up
Patent: 67886
Patent: COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE L'OEDÈME MACULAIRE (COMPOSITIONS AND METHODS FOR TREATMENT OF MACULAR EDEMA)
Estimated Expiration: ⤷ Sign Up
Patent: 32444
Patent: ANTAGONISTES LFA-1 TOPIQUES POUR UNE UTILISATION DANS LE TRAITEMENT LOCALISÉ DE TROUBLES IMMUNITAIRES ASSOCIÉS (TOPICAL LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS)
Estimated Expiration: ⤷ Sign Up
Patent: 97775
Patent: COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE LA RÉTINOPATHIE DIABÉTIQUE (COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 08037
Estimated Expiration: ⤷ Sign Up
Patent: 11500683
Estimated Expiration: ⤷ Sign Up
Patent: 11516607
Estimated Expiration: ⤷ Sign Up
Patent: 11518155
Estimated Expiration: ⤷ Sign Up
Patent: 11521896
Estimated Expiration: ⤷ Sign Up
Patent: 14132032
Patent: TOPICAL LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS
Estimated Expiration: ⤷ Sign Up
Patent: 14132033
Patent: AEROSOLIZED LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS
Estimated Expiration: ⤷ Sign Up
Patent: 14133751
Patent: DELIVERY OF LFA-1 ANTAGONISTS TO GASTROINTESTINAL SYSTEM
Estimated Expiration: ⤷ Sign Up
Patent: 14221808
Patent: 糖尿病性網膜症の治療のための組成物及び方法 (COMPOSITION AND METHOD FOR TREATMENT OF DIABETIC RETINOPATHY)
Estimated Expiration: ⤷ Sign Up
Patent: 16128515
Patent: 免疫関連障害の局所治療に使用するためのエアゾール化ＬＦＡ−１アンタゴニスト (AEROSOLIZED LFA-1 ANTAGONIST TO BE USED FOR TOPICAL TREATMENT OF IMMUNE RELATED DISORDERS)
Estimated Expiration: ⤷ Sign Up
Patent: 16153432
Patent: 胃腸系へのＬＦＡ−１アンタゴニストの送達 (DELIVERY OF LFA-1 ANTAGONISTS TO GASTROINTESTINAL SYSTEM)
Estimated Expiration: ⤷ Sign Up
Patent: 17141310
Patent: 免疫関連障害の局所治療に使用するためのエアゾール化ＬＦＡ−１アンタゴニスト (AEROSOLIZED LFA-1 ANTAGONIST TO BE USED FOR TOPICAL TREATMENT OF IMMUNE RELATED DISORDERS)
Estimated Expiration: ⤷ Sign Up
Patent: 18127485
Patent: 胃腸系へのＬＦＡ−１アンタゴニストの送達 (DELIVERY OF LFA-1 ANTAGONISTS TO GASTROINTESTINAL SYSTEM)
Estimated Expiration: ⤷ Sign Up
Patent: 20023546
Patent: 胃腸系へのＬＦＡ−１アンタゴニストの送達 (DELIVERY OF LFA-1 ANTAGONISTS TO GASTROINTESTINAL SYSTEM)
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 10004281
Patent: COMPOSICIONES Y METODOS PARA EL TRATAMIENTO DE LA RETINOPATIA DIABETICA. (COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY.)
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 30406
Estimated Expiration: ⤷ Sign Up
Patent: 63703
Estimated Expiration: ⤷ Sign Up
Patent: 30024
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering XIIDRA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2017265071 | LFA-1 inhibitor and polymorph thereof | ⤷ Sign Up |
| Japan | 2015187165 | 眼障害の治療のための組成物および方法 (COMPOSITION AND METHOD FOR TREATMENT OF EYE DISORDER) | ⤷ Sign Up |
| Cyprus | 1112844 | ⤷ Sign Up | |
| Canada | 2960117 | COMPOSITIONS ET PROCEDES POUR LE TRAITEMENT DES TROUBLES OCULAIRES (COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS) | ⤷ Sign Up |
| Spain | 2830024 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for XIIDRA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2444079 | C02444079/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: LIFITEGRAST; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66850 19.12.2018 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
